{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:57:59Z","timestamp":1760785079303},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The overall survival for patients with resectable PDAC following curative surgical resection hasn\u2019t been improved significantly, as a considerable proportion of patients develop recurrence within a year. The purpose of this study was to develop and validate a predictive model to assess recurrence risk in patients with PDAC after upfront surgery by using preoperative clinical data and CT characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The predictive model was developed based on a retrospective set of 141 pancreatic cancer patients after surgery. A separate set of 77 patients was used to validate model. Between January 2017 and December 2019, all patients underwent multidetector pancreatic CT and upfront surgery. Univariable and multivariate Cox regression was used to determine the risk factors related to recurrence and then establish a nomogram to estimate the 1-year recurrence probability. The Harrell C-index was employed in evaluating the discrimination and calibration of the model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 218 patients in this retrospective cohort. A recurrence model in nomogram form was developed with predictors including tumor size (hazard ratio [HR], 1.277; 95% CI 1.098, 1.495; <jats:italic>P<\/jats:italic>\u2009=\u20090.002), tumor density in the portal vein phase (HR, 0.598; 95% CI 0.424, 0.844; <jats:italic>P<\/jats:italic>\u2009=\u20090.003), peripancreatic infiltration (HR, 4.151; 95% CI 2.077, 8.298; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), suspicious metastatic lymph node (HR, 2.561; 95% CI 1.653, 3.967; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), Neutrophils\/Lymphocytes ratio (HR, 1.111; 95% CI 1.016, 1.215; <jats:italic>P<\/jats:italic>\u2009=\u20090.020). The predictive nomogram had good discrimination capability with these predictors with an area under curve at 1\u00a0year of 0.84 (95%CI 0.77, 0.91) in the development set and 0.82 (95% CI 0.72, 0.92) and 0.84 (95% CI 0.74, 0.94) in the validation set for two radiologists reading respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The model developed based on preoperative clinical data and CT characteristics of resectable pancreatic ductal adenocarcinoma patients, which can helpfully estimate the recurrence-free survival. It may be a useful tool for clinician to select optimal candidates for upfront surgery or neoadjuvant therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00823-4","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T13:02:23Z","timestamp":1656853343000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics"],"prefix":"10.1186","volume":"22","author":[{"given":"Ningzi","family":"Tian","sequence":"first","affiliation":[]},{"given":"Dong","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[]},{"given":"Mengsu","family":"Zeng","sequence":"additional","affiliation":[]},{"given":"Jianke","family":"Li","sequence":"additional","affiliation":[]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"issue":"26","key":"823_CR1","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.3748\/wjg.v21.i26.7988","volume":"21","author":"QJ Lin","year":"2015","unstructured":"Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Gastroenterol. 2015;21(26):7988\u20138003.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"823_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hpb.12078","volume":"16","author":"J He","year":"2014","unstructured":"He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014;16(1):83\u201390.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"823_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"823_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936\u201345.","journal-title":"Ann Surg"},{"issue":"6","key":"823_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes I, Molenaar IQ, Cameron JL, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154\u201362.","journal-title":"Ann Surg"},{"issue":"4","key":"823_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jamcollsurg.2015.12.031","volume":"222","author":"AA Parikh","year":"2016","unstructured":"Parikh AA, Maiga A, Bentrem D, Squires MR, Kooby DA, Maithel SK, Weber SM, Cho CS, Katz M, Martin RC, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. 2016;222(4):448\u201356.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"823_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21873\/anticanres.13952","volume":"40","author":"K Furukawa","year":"2020","unstructured":"Furukawa K, Shiba H, Hamura R, Haruki K, Fujiwara Y, Usuba T, Nakabayashi Y, Misawa T, Okamoto T, Yanaga K. Prognostic factors in patients with recurrent pancreatic cancer: a multicenter database analysis. Anticancer Res. 2020;40(1):293\u20138.","journal-title":"Anticancer Res"},{"issue":"7","key":"823_CR8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/bjs.11144","volume":"106","author":"YI Kim","year":"2019","unstructured":"Kim YI, Song KB, Lee YJ, Park KM, Hwang DW, Lee JH, Shin SH, Kwon JW, Ro JS, Kim SC. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019;106(7):898\u2013909.","journal-title":"Br J Surg"},{"issue":"3","key":"823_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jso.26510","volume":"124","author":"S Narayanan","year":"2021","unstructured":"Narayanan S, AlMasri S, Zenati M, Nassour I, Chopra A, Rieser C, Smith K, Oyefusi V, Daum T, Bahary N, et al. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. J Surg Oncol. 2021;124(3):308\u201316. https:\/\/doi.org\/10.1002\/jso.26510.","journal-title":"J Surg Oncol"},{"issue":"5","key":"823_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.hbpd.2018.09.003","volume":"17","author":"NH Kim","year":"2018","unstructured":"Kim NH, Kim HJ. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection. Hepatobiliary Pancreat Dis Int. 2018;17(5):450\u20135.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"823_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, et al. Pancreatic adenocarcinoma, version 1. 2019. J Natl Compr Cancer Netw. 2019;17(3):202\u201310.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"823_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del CM, et al. Pancreatic adenocarcinoma, Version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(4):439\u201357.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10242","key":"823_CR13","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"23","key":"823_CR14","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-17-3668","volume":"24","author":"EJ Koay","year":"2018","unstructured":"Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas F, Hobbs BP, Ye R, Elganainy D, Almahariq M, et al. A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2018;24(23):5883\u201394.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"823_CR15","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1\u201373.","journal-title":"Ann Intern Med"},{"issue":"2","key":"823_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging: the eighth edition ajcc cancer staging manual. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"823_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.13131184","volume":"270","author":"MM Al-Hawary","year":"2014","unstructured":"Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, Macari M, Megibow AJ, Miller FH, Mortele KJ, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Radiology. 2014;270(1):248\u201360.","journal-title":"Radiology"},{"issue":"5","key":"823_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.pan.2018.05.005","volume":"18","author":"M Adamu","year":"2018","unstructured":"Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger HD, Weitz J, Rahbari NN. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology. 2018;18(5):585\u201391.","journal-title":"Pancreatology"},{"issue":"4","key":"823_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/bjs.11111","volume":"106","author":"M Strijker","year":"2019","unstructured":"Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, Wilmink JW, Groot KB, van Laarhoven HW, Besselink MG. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Br J Surg. 2019;106(4):342\u201354.","journal-title":"Br J Surg"},{"key":"823_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00001","author":"EJ Koay","year":"2019","unstructured":"Koay EJ, Katz MHG, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, et al. Computed tomography\u2013based biomarker outcomes in a prospective trial of preoperative FOLFIRINOX and chemoradiation for borderline resectable pancreatic cancer. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.19.00001.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"823_CR21","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.3390\/cancers12123656","volume":"12","author":"M Zaid","year":"2020","unstructured":"Zaid M, Widmann L, Dai A, Sun K, Zhang J, Zhao J, Hurd MW, Varadhachary GR, Wolff RA, Maitra A, et al. Predictive modeling for voxel-based quantification of imaging-based subtypes of pancreatic ductal adenocarcinoma (PDAC): a multi-institutional study. Cancers. 2020;12(12):3656. https:\/\/doi.org\/10.3390\/cancers12123656.","journal-title":"Cancers"},{"issue":"5","key":"823_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002664","volume":"95","author":"L Zhu","year":"2016","unstructured":"Zhu L, Shi X, Xue H, Wu H, Chen G, Sun H, He Y, Jin Z, Liang Z, Zhang Z. CT imaging biomarkers predict clinical outcomes after pancreatic cancer surgery. Medicine. 2016;95(5): e2664.","journal-title":"Medicine"},{"issue":"2","key":"823_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1148\/radiol.2018172331","volume":"288","author":"S Lee","year":"2018","unstructured":"Lee S, Kim SH, Park HK, Jang KT, Hwang JA, Kim S. Pancreatic ductal adenocarcinoma: rim enhancement at MR imaging predicts prognosis after curative resection. Radiology. 2018;288(2):456\u201366.","journal-title":"Radiology"},{"issue":"8","key":"823_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/MPA.0b013e3181dbc583","volume":"39","author":"Y Hattori","year":"2010","unstructured":"Hattori Y, Gabata T, Zen Y, Mochizuki K, Kitagawa H, Matsui O. Poorly enhanced areas of pancreatic adenocarcinomas on late-phase dynamic computed tomography: comparison with pathological findings. Pancreas. 2010;39(8):1263\u201370.","journal-title":"Pancreas"},{"issue":"2","key":"823_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00261-008-9460-0","volume":"35","author":"H Hata","year":"2010","unstructured":"Hata H, Mori H, Matsumoto S, Yamada Y, Kiyosue H, Tanoue S, Hongo N, Kashima K. Fibrous stroma and vascularity of pancreatic carcinoma: correlation with enhancement patterns on CT. Abdom Imaging. 2010;35(2):172\u201380.","journal-title":"Abdom Imaging"},{"issue":"4","key":"823_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ejrad.2013.12.016","volume":"83","author":"Y Fukukura","year":"2014","unstructured":"Fukukura Y, Takumi K, Higashi M, Shinchi H, Kamimura K, Yoneyama T, Tateyama A. Contrast-enhanced CT and diffusion-weighted MR imaging: performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma. Eur J Radiol. 2014;83(4):612\u20139.","journal-title":"Eur J Radiol"},{"issue":"16","key":"823_CR27","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol"},{"issue":"3","key":"823_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo.2016.3616","volume":"49","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang W, Yuan X, Fu M, Qian H, Xu W. Neutrophils in cancer development and progression: Roles, mechanisms, and implications (Review). Int J Oncol. 2016;49(3):857\u201367.","journal-title":"Int J Oncol"},{"issue":"1","key":"823_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, Mcmillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"823_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/bjc.2013.332","volume":"109","author":"M Stotz","year":"2013","unstructured":"Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, Alzoughbi W, Seggewies FS, Lackner C, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416\u201321.","journal-title":"Br J Cancer"},{"issue":"2","key":"823_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/SLA.0000000000001988","volume":"266","author":"G Gemenetzis","year":"2017","unstructured":"Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, Lennon AM, Wood LD, Hruban RH, Zheng L, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266(2):339\u201345.","journal-title":"Ann Surg"},{"issue":"1","key":"823_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.amjsurg.2019.04.014","volume":"219","author":"T Matsumoto","year":"2020","unstructured":"Matsumoto T, Okabayashi T, Sui K, Morita S, Iwata J, Shimada Y. Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients. Am J Surg. 2020;219(1):93\u20138.","journal-title":"Am J Surg"},{"issue":"1","key":"823_CR33","doi-asserted-by":"publisher","first-page":"18758","DOI":"10.1038\/s41598-020-75745-8","volume":"10","author":"N Iwai","year":"2020","unstructured":"Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep. 2020;10(1):18758.","journal-title":"Sci Rep"},{"issue":"9","key":"823_CR34","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.21873\/anticanres.12883","volume":"38","author":"T Sakamoto","year":"2018","unstructured":"Sakamoto T, Saito H, Uchinaka EI, Morimoto M, Amisaki M, Tokuyasu N, Honjo S, Ashida K, Fujiwara Y. The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19\u20139 level as a prognostic indicator in patients with recurrent pancreatic cancer. Anticancer Res. 2018;38(9):5497\u2013503.","journal-title":"Anticancer Res"},{"issue":"1","key":"823_CR35","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.14701\/ahbps.BP-OP-1-4","volume":"25","author":"S Hong","year":"2021","unstructured":"Hong S, Song KB, Hwang DW, Lee JH, Lee W, Kwon J, Park Y, Kim SC. Preoperative serum carbohydrate antigen 19\u20139 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Ann Hepato-Biliary-Pancreatic Surg. 2021;25(1):S77.","journal-title":"Ann Hepato-Biliary-Pancreatic Surg"},{"issue":"6","key":"823_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MPA.0000000000001066","volume":"47","author":"H Kurahara","year":"2018","unstructured":"Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, et al. A Therapeutic strategy for resectable pancreatic cancer based on risk factors of early recurrence. Pancreas. 2018;47(6):753\u20138.","journal-title":"Pancreas"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00823-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T13:02:30Z","timestamp":1656853350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00823-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the Ethics Committee of the FUZS hospital and requirement for informed patient consent was waived as a retrospective study. This study was not referred patient interactions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}